MindMed Corporate Presentation 4-12-2021
Post# of 64
Click here to download!
----
MindMed Has Pioneered a New Asset Class
Psychedelic Inspired Medicine is The Latest Advancement in Biotech
MindMed Corporate Presentation | April 2021
Strict Regulatory
Adherence & FDA Process:
Patients deserve more effective medicine and therapies for mental health and addiction
Most diversified & extensive psychedelic development pipeline in the psychedelics industry
Aquisitive clinical trial approachis cost efficience and effective
Unique focus on all stages of development and delivery - From discovery to insurance
$1.7 Billion Comparable Drug Value
$4.7B Global annual Anxiety drug sales
$9.5B Global annual drug sales ADHD
$5.8B Global annual Anti-Addiction drug sales
$9.6B Global annual Depression drug sales